European manufacturers must act to stop misuse of devices or face new regulation
This article was originally published in Clinica
The medical devices industry needs to draw up a code of practice urgently to prove it is doing everything in its power to limit the misuse of products by users. If manufacturers delay in addressing this issue, they risk prosecution and the industry as a whole will be vulnerable to further regulatory controls, according to medical device expert Dario Pirovano.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.